Advances in Ovarian Cancer: Using Genomics and Optimizing Maintenance TherapyByAmy VanGalder, PharmD, BCOPMay 18th 2025
Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?BySang Chau, PharmD, BCOP,Justin Tse, PharmD, BCOP,Amy VanGalder, PharmD, BCOP,Garrick Wong, PharmD,Terra Wonsettler, PharmD, MBA,Andrew Hertler, MD, FACPJune 12th 2024
